{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T05:10:25Z","timestamp":1791954625506,"version":"4.3.4"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,10,1]]},"DOI":"10.1093\/mmy\/myu036","type":"journal-article","created":{"date-parts":[[2014,7,22]],"date-time":"2014-07-22T01:12:11Z","timestamp":1405991531000},"page":"699-705","source":"Crossref","is-referenced-by-count":20,"title":["Relapsed and secondary disease drive the risk profile for invasive aspergillosis prior to stem cell transplantation in patients with acute myeloid leukemia or myelodysplastic syndrome"],"prefix":"10.1093","volume":"52","author":[{"given":"Robert J.","family":"van de Peppel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf M.","family":"Dekkers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"von dem Borne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark G. J.","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2014,7,21]]},"reference":[{"key":"key\n\t\t\t\t20171012041957_bib1","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1086\/318483","article-title":"Aspergillosis case-fatality rate: systematic review of the literature","volume":"32","author":"Lin","year":"2001","journal-title":"Clin Inf Dis"},{"key":"key\n\t\t\t\t20171012041957_bib2","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"NJM"},{"key":"key\n\t\t\t\t20171012041957_bib3","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1086\/595846","article-title":"Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry","volume":"48","author":"Neofytos","year":"2009","journal-title":"Clin Inf Dis"},{"key":"key\n\t\t\t\t20171012041957_bib4","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s12026-012-8274-x","article-title":"Host immune defense against Aspergillus fumigatus: insight from experimental systemic (disseminated) infection","volume":"52","author":"Mirkov","year":"2012","journal-title":"Imm Res"},{"issue":"Suppl 1","key":"key\n\t\t\t\t20171012041957_bib5","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.3109\/13693786.2010.505204","article-title":"Clinical risk factors for invasive aspergillosis","volume":"49","author":"Baddley","year":"2011","journal-title":"Med Myco"},{"key":"key\n\t\t\t\t20171012041957_bib6","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3109\/00365548.2011.623311","article-title":"Risk factors for invasive mold infections following allogeneic hematopoietic stem cell transplantation: a single center study of 190 recipients","volume":"44","author":"Li","year":"2012","journal-title":"Scand J Inf Dis"},{"key":"key\n\t\t\t\t20171012041957_bib7","doi-asserted-by":"crossref","first-page":"4358","DOI":"10.1182\/blood-2002-05-1496","article-title":"Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors","volume":"100","author":"Marr","year":"2002","journal-title":"Blood"},{"key":"key\n\t\t\t\t20171012041957_bib8","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/1097-0142(19840201)53:3<411::AID-CNCR2820530308>3.0.CO;2-E","article-title":"Multivariate analysis of factors associated with invasive fungal disease during remission induction therapy for acute myelogenous leukemia","volume":"53","author":"Schwartz","year":"1984","journal-title":"Cancer"},{"key":"key\n\t\t\t\t20171012041957_bib9","article-title":"SWAB Guidelines for the Management of Invasive Fungal Infections","author":"Kullberg","year":"2009"},{"key":"key\n\t\t\t\t20171012041957_bib10","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1093\/cid\/ciq147","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin Inf Dis"},{"key":"key\n\t\t\t\t20171012041957_bib11","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/bmt.2010.175","article-title":"European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3\u20142009 update","volume":"46","author":"Maertens","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"key\n\t\t\t\t20171012041957_bib12","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1128\/JCM.00335-12","article-title":"Molecular epidemiology of Aspergillus fumigatus isolates harboring the TR34\/L98H azole resistance mechanism","volume":"50","author":"Camps","year":"2012","journal-title":"J Clin Microbiol"},{"key":"key\n\t\t\t\t20171012041957_bib13","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1056\/NEJMe068266","article-title":"Prophylaxis and aspergillosis\u2014has the principle been proven?","volume":"356","author":"De Pauw","year":"2007","journal-title":"New En. J Med"},{"key":"key\n\t\t\t\t20171012041957_bib14","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.3201\/eid1710.110226","article-title":"Clinical implications of azole resistance in Aspergillus fumigatus, The Netherlands, 2007\u20132009","volume":"17","author":"van der Linden","year":"2011","journal-title":"Emerg Inf Dis"},{"key":"key\n\t\t\t\t20171012041957_bib15","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/1469-0691.12002","article-title":"Invasive fungal diseases in haematopoietic cell transplant recipients and in patients with acute myeloid leukaemia or myelodysplasia in Brazil","volume":"19","author":"Nucci","year":"2013","journal-title":"Clin Microbiol Inf"},{"key":"key\n\t\t\t\t20171012041957_bib16","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.bbmt.2009.06.019","article-title":"Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective","volume":"15","author":"Tomblyn","year":"2009","journal-title":"Blood Marrow Transplant"},{"key":"key\n\t\t\t\t20171012041957_bib17","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","article-title":"Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) Consensus Group","volume":"46","author":"De Pauw","year":"2008","journal-title":"Clin Inf Dis"},{"key":"key\n\t\t\t\t20171012041957_bib18","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1093\/jac\/dkq121","article-title":"Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort","volume":"65","author":"Vehreschild","year":"2010","journal-title":"J Antimicrob Chem"},{"key":"key\n\t\t\t\t20171012041957_bib19","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.2165\/00003495-200767110-00004","article-title":"Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients","volume":"67","author":"Maschmeyer","year":"2007","journal-title":"Drugs"},{"key":"key\n\t\t\t\t20171012041957_bib20","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1093\/jac\/dkp464","article-title":"Safety of triazole antifungal drugs in patients with cancer","volume":"165","author":"Cronin","year":"2010","journal-title":"J Antimicobiol Chemo"},{"key":"key\n\t\t\t\t20171012041957_bib21","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/bmt.2009.325","article-title":"Drug interactions and adverse events associated with antimycotic drugs used for invasive aspergillosis in hematopoietic SCT","volume":"45","author":"Egger","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"key\n\t\t\t\t20171012041957_bib22","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1365-2141.2011.08838.x","article-title":"Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation","volume":"155","author":"Marks","year":"2011","journal-title":"Brit J Haematol"},{"key":"key\n\t\t\t\t20171012041957_bib23","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s11908-011-0218-4","article-title":"Azole antifungal resistance today: focus on Aspergillus","volume":"13","author":"Bowyer","year":"2011","journal-title":"Curr Inf Dis Rep"}],"container-title":["Medical Mycology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/mmy\/article-pdf\/52\/7\/699\/9349178\/myu036.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,10,12]],"date-time":"2017-10-12T04:20:07Z","timestamp":1507782007000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/mmy\/article\/52\/7\/699\/2812273\/Relapsed-and-secondary-disease-drive-the-risk"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,21]]},"references-count":23,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2014,7,21]]},"published-print":{"date-parts":[[2014,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/mmy\/myu036","relation":{},"ISSN":["1460-2709","1369-3786"],"issn-type":[{"value":"1460-2709","type":"electronic"},{"value":"1369-3786","type":"print"}],"subject":[],"published-other":{"date-parts":[[2014,10]]},"published":{"date-parts":[[2014,7,21]]}}}